Ependymoma from Benign to Highly Aggressive Diseases: A Review

Adv Tech Stand Neurosurg. 2024;50:31-62. doi: 10.1007/978-3-031-53578-9_2.ABSTRACTEpendymomas comprise biologically distinct tumor types with respect to age distribution, (epi)genetics, localization, and prognosis. Multimodal risk-stratification, including histopathological and molecular features, is essential in these biologically defined tumor types. Gross total resection (GTR), achieved with intraoperative monitoring and neuronavigation, and if necessary, second-look surgery, is the most effective treatment. Adjuvant radiation therapy is mandatory in high-risk tumors and in case of residual tumor. There is yet growing evidence that some ependymal tumors may be cured by surgery alone. To date, the role of chemotherapy is unclear and subject of current studies.Even though standard therapy can achieve reasonable survival rates for the majority of ependymoma patients, long-term follow-up still reveals a high probability of relapse in certain biological entities.With increasing knowledge of biologically distinct tumor types, risk-adapted adjuvant therapy gains importance. Beyond initial tumor control, and avoidance of therapy-induced morbidity for low-risk patients, intensified treatment for high-risk patients comprises another challenge. With identification of specific risk features regarding molecular alterations, targeted therapy may represent an option for individualized treatment modalities in the future.PMID:38592527 | DOI:10.1007/978-3-031-53578-9_2

Source: Cancer Control - April 9, 2024 Category: Cancer & Oncology Authors: Stephanie T J ünger Valentina Zschernack Martina Messing-J ünger Beate Timmermann Torsten Pietsch Source Type: research